Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

The New England journal of medicine - 14 Jun 2018

Socinski Mark A, Jotte Robert M, Cappuzzo Federico, Orlandi Francisco, Stroyakovskiy Daniil, Nogami Naoyuki, Rodríguez-Abreu Delvys, Moro-Sibilot Denis, Thomas Christian A, Barlesi Fabrice, Finley Gene, Kelsch Claudia, Lee Anthony, Coleman Shelley, Deng Yu, Shen Yijing, Kowanetz Marcin, Lopez-Chavez Ariel, Sandler Alan, Reck Martin

Abstract excerpt

BACKGROUND: The cancer-cell-killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor-mediated immunosuppression with bevacizumab. This open-label, phase 3 study evaluated atezolizumab plus bevacizumab plus chemotherapy in patients with metastatic nonsquamous non-small-cell lung cancer (NSCLC) who had not previously received chemotherapy. METHODS: We randomly assigned...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Bevacizumab

Share to Carboplatin

Share to Genes, erbB-1

Share to Immunotherapy

Share to Paclitaxel

Source

Identifiers

PMID: 29863955
DOI: 10.1056/NEJMoa1716948

Genes

ALK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.PMID 29863955Read ↗

Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations.Semantic proximity Read ↗

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial.Semantic proximity Read ↗

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.Semantic proximity Read ↗

A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).Semantic proximity Read ↗

Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation Study in Ibaraki Group (ATTENTION-IBARAKI).Semantic proximity Read ↗

Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation.Semantic proximity Read ↗

Efficacy of atezolizumab, bevacizumab, carboplatin, and paclitaxel for epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after tyrosine kinase inhibitor failure.Semantic proximity Read ↗

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis.Semantic proximity Read ↗

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial.Semantic proximity Read ↗

Development and validation of a blood-based genomic mutation signature to predict the clinical outcomes of atezolizumab therapy in NSCLC.Semantic proximity Read ↗

Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study).Semantic proximity Read ↗

NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.